Navigation Links
Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society
Date:10/27/2009

SAN DIEGO, Oct. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced results from new intent to treat (ITT) analyses from the COR-I and COR-II Phase 3 trials of Contrave® (naltrexone SR/bupropion SR), the first of two late stage Orexigen candidates for the treatment of obesity. These data expand on top-line results announced in July and complement findings from a panel discussion on Saturday where the Company presented data on Contrave patients who completed 56 weeks of therapy. These ITT data were presented today in two late breaker oral presentations at the 27th Annual Scientific Meeting of The Obesity Society in Washington, D.C.

Results showed that, on an ITT basis,

  • Approximately 25-33% lost 10% or more of their body weight and 12-16% lost at least 15%; and
  • Obese patients on Contrave demonstrated significant improvements in important markers of cardiometabolic risk including waist circumference, HDL and triglycerides

"The data presented today and on Saturday provide a deeper view of Contrave, and what we believe is a balanced efficacy and safety profile," said Eduardo Dunayevich, M.D., Chief Medical Officer of Orexigen. "These findings should help clinicians assess the potential value of Contrave pharmacotherapy in managing obesity and support our belief that if approved, Contrave could meet the broad range of needs of this patient population by virtue of its efficacy, safety and benefits on key markers of cardiometabolic risk."

Additional data from today's late breaker presentations are outlined in the below table:

    Efficacy Result(+)
                                    COR-I                       COR-II
    --------------------------------------------------------------------------
                               PBO 
'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen(R) Initiates Second Phase IIb Empatic(TM) Trial on Schedule
2. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
3. Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
4. Orexigen(R) Therapeutics Schedules July 20, 2009 Teleconference and Webcast Discussion of Contrave(R) Phase 3 Results
5. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... --  Memorial Hermann Health System and The University ... new partnership to provide a new level of specialized breast ... the greater Houston area. ... provider of professional breast radiology services for five of Memorial ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... 2014  Publicis Groupe customer engagement agency ... and Healthcare Industry Group Leader, has been featured in ... most inspiring people in the life-sciences industry. Those chosen ... development, marketing, technology, creativity, strategy and medicine. ... partner in its leading Rosetta Consulting practice. In 2012, ...
(Date:8/21/2014)... HAMBURG, Germany , Aug. 21, 2014 /PRNewswire/ ... collaborating with Deutsches Elektronen-Synchrotron ( DESY ), a leading ... to speed up management and storage of massive volumes ... Analytics architecture based on IBM software defined technology ... data at peak performance and help scientists worldwide gain ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Shannon Hartley Shines in PharmaVOICE 100 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... FOREST, Ill., Aug. 17, 2011 Hospira, Inc. (NYSE: ... and medication delivery company, today announced that William G. ... directors. Dempsey brings strong executive management and diverse global ... The addition of Dempsey expands Hospira,s board to 11 ...
... Leading dermatologist Dr. Arielle Kauvar announces ... Care , now offers the newest generation of the ... GlideSafe™ Handpieces. The Pelleve System from Ellman International provides ... Dr. Kauvar is known for offering effective, ...
Cached Medicine Technology:Hospira Expands Board of Directors 2New York Dermatologist Offers the Latest in Pelleve Wrinkle Reduction Technology 2
(Date:8/21/2014)... 21, 2014 The City of Garden ... entertainment and programming for its inaugural “Re:Imagine Garden Grove ... 12, 2014, from 11 a.m. to 4 p.m., 2.85-miles ... cars and the downtown will be filled with diverse ... Community Arts Resources (CARS), for all to enjoy. , ...
(Date:8/21/2014)... Aug. 21, 2014 (HealthDay News) -- Among seniors, dimming ... The study involved more than 2,500 people, aged 65 ... study and again two, six and eight years later. ... the person,s risk of death during the study period, the ... effect, researchers led by Sharon Christ of Purdue University in ...
(Date:8/21/2014)... 21, 2014 A new study published ... increase in disability associated with speech problems from 2001-02 ... than 15% increase in disability associated with hearing problems. ... rising numbers of children who are experiencing communication disorders, ... , On a broader level, the new study, ...
(Date:8/21/2014)... Aug. 21, 2014 Researchers in the United Kingdom ... can quickly and accurately diagnose a number of rare ... study published online today in Ophthalmology , ... Using a single test, doctors were able to tailor ... mutations reducing the time and money spent on diagnosis ...
(Date:8/21/2014)... The report "Industrial Flue Gas Treatment Systems & ... Particulate Control, Mercury Control) by Application (Power Generation, ... Global Trends & Forecasts to 2019" defines and ... & services market with analysis and projection of ... The industrial flue gas treatment systems & services ...
Breaking Medicine News(10 mins):Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 2Health News:New Pediatrics Study Reveals Dramatic Increase in Speech Problems in Children Over Past Decade 3Health News:New DNA test for diagnosing diseases linked to childhood blindness 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4
... have felt elated using the tanning beds and cannot seem ... the elation than just the look good factor of the ... , have researched the background of the ‘feel good’ ... tan could also be igniting euphoric sensations, akin to the ...
... Jerry Mendell a neurologist, co-director of the Muscular ... professor of pediatrics, neurology and pathology at Ohio ... the Neuromuscular Research Program and Gene Therapy Center ... injection of Asklepios Biopharmaceutical Inc (AskBio’s) Biostrophin, which ...
... 570,000 children under the age of 15 die of AIDS ... - states a new global report highlighting concerns about the ... the World Health Organization (WHO) and the Joint United Nations ... HIV ART in low- and middle- income countries more than ...
... Rayburn, a cardiologist from the University of Alabama, Birmingham, told ... the drug showed no significant difference in the rate of ... or placebos. The drug Vioxx is produced and marketed by ... told a jury that the studies, covering a total of ...
... At fairing well in examining the heart and making ... They fair better than medical students, residents, and other ... in accurately identifying abnormal heart sounds. This was revealed ... Archives of Internal Medicine. ,The study was performed ...
... A new study has found that smoking and drinking at ... has exposed the adverse effects of tobacco and alcohol has ... second leading cause of cancer deaths, and doctors generally recommend ... Typically, the disease is diagnosed in people in their late ...
Cached Medicine News:Health News:Wider Addictive Choices – Now, Tanned Addicts 2Health News:Trial Of DMD Gene Therapy Initiated At Ohio 2Health News:AIDS Deaths On The Rise Due To Low Access To Antiretroviral Treatment 2Health News:Could Long Tern Vioxx Users Suffer From Heart Attacks? 2